A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
Malignancies Multiple
DRUG: BMS-986205|DRUG: Itraconazole|DRUG: Rifampin
Maximum observed plasma concentration (Cmax), Measured by plasma concentration, Up to 25 days|AUC from time zero to time of last quantifiable concentration (AUC(0-T)), Measured by plasma concentration, Up to 25 days|AUC from time zero extrapolated to infinite time (AUC(INF)), Measured by plasma concentration, Up to 25 days
Incidence of Adverse Events (AEs), Safety and tolerability as measured by incidence of AEs, Up to 25 days|Incidence of Serious Adverse Events (SAEs), Safety and tolerability as measured by incidence of SAEs, Up to 76 days|Number of participants with electrocardiogram abnormalities, Up to 25 days|Number of participants with physical examination findings abnormalities, Up to 25 days|Number of participants with clinical laboratory abnormalities, Up to 25 days
A randomized, open-label, parallel design study in healthy participants to assess the effects of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and tolerability data to be collected and assessed as well.